5 hours ago
Aarti Drugs posted a strong set of Q1 numbers, with net profit rising nearly 63% year-on-year on the back of improved margins and steady revenue growth.
Aarti Drugs Ltd reported a robust financial performance for the quarter ended June 2025, with net profit soaring 62.7% year-on-year to ₹54 crore, compared to ₹33.2 crore in the same quarter last year. The growth in profitability was supported by higher operational efficiency and margin expansion.
Revenue for the quarter stood at ₹590 crore, up 6.3% from ₹555 crore a year ago. The company also saw a healthy improvement in EBITDA, which rose 14% YoY to ₹74 crore versus ₹65 crore last year.
Operating margins expanded to 12.6%, up from 11.7% in Q1 FY25, indicating better cost control and a favourable product mix.
Also Read: Hindustan Zinc Q1 Results: Topline misses estimates but margin holds firm
Ahead of the earnings announcement, shares of Aarti Drugs closed 0.87% higher at ₹522.30 apiece on the NSE.
Also Read: Dr Reddy’s Q1 earnings may defy concerns around blockbuster cancer drug
